FDA approves Spevigo for pustular psoriasis

[Fred]

Update:

Quote:

---

Spevigo approved for expanded indications in China and the US.

In China, Spevigo's expanded approval adds the reduction of occurrences of GPP in pediatric patients aged 12 and above weighing ≥40 kg, and adults.

The US FDA’s approval expands the use of Spevigo to include the treatment of GPP in adults and pediatric patients aged 12 and above weighing ≥40 kg, making it the first targeted therapy that addresses the need for acute and chronic treatment for GPP patients.

Spevigo is currently approved in 48 countries.

boehringer-ingelheim

Spevigo (spesolimab)